Prevention of Incisional Hernia With Mesh-suture at Umbilical Trocar Site.

NCT ID: NCT06251583

Last Updated: 2024-02-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

124 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-22

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Incisional hernia related to the umbilical trocar site is probably the most frequent complication after laparoscopic surgical procedures. However, this is an underestimated sequelae of laparoscopic surgery which may involve an important morbidity and an increase in healthcare costs.

The incidence of incisional trocar site hernia ranges from 20 to 35% of patients after laparoscopic surgery depending on the different investigations. Prophylactic meshes have been tried in an attempt to reduce the incidence of this complication in obese patients. In that sense, suture-meshes can be an alternative to conventional meshes to improve the incidence of incisional hernias.

INDURATE TRIAL aims to test if suture-mesh is capable of reducing the incidence of incisional hernia in patients with risk factors for the development of this frequent complication when compared with conventional monofilament sutures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incisional Hernia of Anterior Abdominal Wall Dehiscence Wound Wound Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group or Duramesh group

Umbilical trocar closure using Suture-mesh (Duramesh suture).

Group Type EXPERIMENTAL

duramesh suture

Intervention Type DEVICE

Duramesh-suture will be used for trocar closure in the experimental group

Control group or poli(4)hidroxibutirate group

Umbilical trocar closure using conventional monofilament suture.

Group Type ACTIVE_COMPARATOR

duramesh suture

Intervention Type DEVICE

Duramesh-suture will be used for trocar closure in the experimental group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

duramesh suture

Duramesh-suture will be used for trocar closure in the experimental group

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (at least 18 year-old patients)
* Umbilical trocar incision \> 10 mm
* Any of the following risk factors: BMI \> 27, Absence of primary umbilical hernia or smaller than 1 cm, active smoking, malnutrition, anemia, oncological surgery, diabetes, heart failure, chronic kidney disease, chronic liver disease, collagen disease, chronic pulmonary disease.

Exclusion Criteria

* Umbilical trocar incision \< 10 mm
* Umbilical hernia \> 10 mm
* Hernia surgery or incisional hernia at the trocar site
* Conversion to laparotomy
* Pregnancy
* Ascites or cirrhosis
* Clasification of the American Anestesiology Classification IV o V.
* Inadequate follow-up
* Patients included in any other trial
* Patients with life expectancy \< 12 months
* Patients with any kind of sensibility to Duramesh
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ana Sánchez Gollarte

UNKNOWN

Sponsor Role collaborator

Álvaro Robin Valle de Lersundi

UNKNOWN

Sponsor Role collaborator

Arturo Cruz Cidoncha

UNKNOWN

Sponsor Role collaborator

Almudena Moreno Elola-Olaso

UNKNOWN

Sponsor Role collaborator

Armando Galván Pérez

UNKNOWN

Sponsor Role collaborator

Ana María Minaya Bravo

UNKNOWN

Sponsor Role collaborator

Enrique González González

UNKNOWN

Sponsor Role collaborator

Carlos Guijarro Moreno

UNKNOWN

Sponsor Role collaborator

Asunción Aguilera Velardo

UNKNOWN

Sponsor Role collaborator

Patricia López Quindos

UNKNOWN

Sponsor Role collaborator

Clara María Martínez Moreno

UNKNOWN

Sponsor Role collaborator

Marina Pérez-Flecha González

UNKNOWN

Sponsor Role collaborator

Victor Vaello Jodra

UNKNOWN

Sponsor Role collaborator

Miguel A ngel Garci-a Urena

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Miguel A ngel Garci-a Urena

Professor Miguel Ángel García Ureña

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Miguel Ángel García Ureña

Madrid, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ana Sánchez Gollarte, MD

Role: primary

651690526

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

INDURATE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.